• On the contrary Birrel and colleagues observed divergent

  2025-02-19

  

  On the contrary, Birrel and colleagues observed divergent proliferative responses to androgens in different BC cell lines: DHT and mibolerone were found to inhibit the T47-D and ZR-75-1 MAFP growth, while the proliferation of MCF-7 cells was increased by both the androgens [53]. It is worth noying

• Recently the FDA approved the first blood based

  2025-02-19

  

  Recently, the FDA approved the first blood-based test for the detection of EGFR mutations in non-small cell lung cancer patients (http://www.fda.gov) (Voelker, 2016). This allows detection of specific, recurrent mutations, which can help the selection of the patients that could benefit from Erlotini

• In this study we demonstrated that DRR protein level in

  2025-02-19

  

  In this study, we demonstrated that DRR1 protein level in GBM tissues was significantly higher compared to normal OPP tissues. This data suggested that DRR1 might play a role in the tumorigenesis of glioma. To investigate whether DRR1 could accurately predict the outcome in patients with glioma, IH

• br Author contributions br Funding This work

  2025-02-19

  

  Author contributions Funding This work was supported by the Czech Science Foundation, project no. 14-16220S. Additional support was provided by NIH R01CA117907 grant awarded to J.M.E. Conflict of interest Introduction The dioxin-like family includes polyhalogenated aromatic hydrocarbons

• plicamycin synthesis br Conflict of Interest br Transparency

  2025-02-19

  

  Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is

• br Ataxia telangiectasia and Rad related as

  2025-02-18

  

  Ataxia–telangiectasia and Rad3 related as a therapeutic target Several concerns revolving around functional inhibition of ATR have hindered the exploitation of ATR as therapeutic target in cancer therapy and delayed the development of specific ATR kinase inhibitors. It was anticipated that pharma

• In addition AMPK reduces protein synthesis

  2025-02-18

  

  In addition, AMPK reduces protein synthesis and stimulates apoptotic and autophagic pathways through the inhibition of the mechanistic target of rapamycin (mTOR), which regulates cellular metabolic homeostasis, insulin secretion, insulin resistance, autophagy and apoptosis (Maiese, 2016). mTOR is th

• Interestingly intermittent high doses of

  2025-02-17

  

  Interestingly, intermittent high doses of AKT inhibitors have been shown to be a more effective strategy both clinically and pre-clinically. High doses appear to be required for induction of apoptosis and intermittent schedules overcome the low therapeutic index of these compounds. This is particula

• AhR was proven to participate

  2025-02-17

  

  AhR was proven to participate in carcinogenesis. Its high expression was demonstrated in a variety of tumors, i.e. pancreatic, prostate, urinary tract, lung and papillary thyroid carcinoma (Safe et al., 2013, Mian et al., 2014). However, cell line studies showed variable AhR levels/responses. AhR kn

• Whether similar mechanisms play a role in adiponectin signal

  2025-02-17

  

  Whether similar mechanisms play a role in adiponectin signal transduction and whether additional proteins are recruited to adiponectin receptors via APPL1 has not been analysed so far. Although it has been clearly established that APPL1 is a downstream adaptor protein in adiponectin signal transduct

• Encouraged by this observation a systematic

  2025-02-17

  

  Encouraged by this observation, a systematic SAR study on the A ring -alkoxy was conducted as summarized in . The A ring methoxy-containing KRCA-0008 was proven an optimal substituent in terms of potency after all and its bigger size derivatives were detrimental in both biochemical and H3122 cellula

• It is worth pointing out that phenotypes of

  2025-02-17

  

  It is worth pointing out that phenotypes of in vivo HSP90β inhibition were not identical to those observed in rapsyn mutant mice (Gautam et al., 1995). Postsynaptically, junctional AChR clusters appeared fragmented, in addition to expected reduction in AChR intensity, in muscles injected with 17-AAG

• Earlier studies revealed an interaction between HSP and ACK

  2025-02-17

  

  Earlier studies revealed an interaction between HSP90β and ACK1 [15]. In the proteomic approach, we show that ACK1 associates with HSP90α and HSP90β. Additionally, we confirm the existence of a HSP90-ACK1 complex with co-IP experiments. We further analysed whether an inhibition of HSP90 affected the

• The cellular mechanism underlying the CGS mediated

  2025-02-17

  

  The cellular mechanism underlying the CGS12066-mediated inhibition of glutamate release from hippocampal nerve terminals through presynaptic 5-HT1B receptors remains to be elucidated. 5-HT1B receptors are coupled to PTX-sensitive G proteins (Gi or Go) that have been shown to inhibit AC activity as w

• Ryoichi et al modified potent clinical candidate VX with

  2025-02-17

  

  Ryoichi et al. modified potent clinical candidate VX-680 (6) with 3-cyano-6-(5-methyl-3-pyrazolamino)pyridine as Aurora kinase inhibitor. Substituted cyano pyridine derivative (7) inhibited proliferation of HCT-116 cells with an IC50 value of 115 nM. It showed tumor inhibition in mice model at a dos

14442 records 7/963 page Previous Next First page 上5页 678910 下5页 Last page